With the announcement that it will no longer be producing the COVID-19 vaccine known as Vaxzevria on a worldwide scale, the vaccine maker AstraZeneca has announced that it will be discontinuing production of the vaccine.
This decision has caused shockwaves to be transmitted through the community of people who work in the field of global health. This decision was made when the business became aware of an unusual adverse event associated with the vaccine that had the potential to be of life-threatening nature.
The Adverse Effects That Are Not Very Common: TTS
Thrombosis with Thrombocytopenia Syndrome (TTS) is the ailment that is being discussed here. This disorder is distinguished by the presence of blood clots in conjunction with a low number of platelets in the blood. At least 81 people have lost their lives and a substantial number of others have had injuries as a result of it in the United Kingdom.
What Should Be Done Regarding the Business?
AstraZeneca contends that the withdrawal is a business decision, citing a surplus of updated vaccines for newer types and a subsequent drop in demand for Vaxzevria2 as the rationale for the move away from the product. On the other hand, the timing correlates with legal challenges that the firm is currently having about the detrimental consequences of the vaccine.
The international pharmaceutical business is currently involved in a legal issue in the United Kingdom, where more than fifty alleged victims and their families are demanding compensation for the harm that was caused by the vaccine.
On an International Scale
Because of the withdrawal of Vaxzevria, a vaccination that was formerly considered a success in the fight against COVID-19 has been removed from the market. This immunization was once considered a victory. In spite of the fact that the vaccine was responsible for saving the lives of more than 6.5 million people in its first year of use, its legacy is today being overshadowed by worries regarding safety.
At the same time that AstraZeneca is finishing up this particular chapter of its reaction to COVID-19, people all around the world are considering the delicate balance that needs to be maintained between the rapid development of vaccines and the protection of the general public.
